Is Anticoagulation Discontinuation Achievable with Citrate Dialysate during HDF Sessions?

Table 3

Association of dialysis circuit coagulation with treatment characteristics.

Parameters	Univariate analysis		Multivariate analysis
	Estimation (±SD)	value	Estimation (±SD)	value	RR (95% CI)
Nadroparine quantity
Baseline versus none	−1.06 ± 0.64	0.098	−1.63 ± 0.58	0.0048	0.20 (0.06–0.61)
Reduced versus none	−0.70 ± 0.43	0.11	−1.04 ± 0.43	0.0146	0.35 (0.15–0.81)
Hemodiafilter
FX versus ELISIO	−0.37 ± 0.43	ns
TS versus ELISIO	−0.38 ± 0.66	ns
VITAPES versus ELISIO	−0.37 ± 0.52	ns
Dialysis machine
AK versus ARTIS	0.83 ± 0.38	0.027	1.97 ± 0.86	0.022	7.15 (1.33–38.4)
Vitamin K antagonists
Present versus Absent	−4.01 ± 0.70	<0.0001	−3.12 ± 0.49	<0.0001	0.04 (0.02–0.11)
Antiplatelet drugs
Aspirin versus none	0.06 ± 0.52	ns
Clopidogrel versus None	0.73 ± 0.51	ns
Association versus none	−0.62 ± 0.89	ns
Iron sucrose (Venofer®)
Present versus absent	−0.68 ± 0.29	0.02	−0.30 ± 0.31	0.33 (ns)
Total blood treated (RR/10 liters)	−0.08 ± 0.02	0.0002	−0.09 ± 0.04	0.0149	0.40 (0.19–0.84)
Ultrafiltration rate	0.00 ± 0.00	ns
Hemoglobin	−0.21 ± 0.17	ns
CRP	0.002 ± 0.01	ns

By univariate and multivariate analysis, the reduction and withdrawal of nadroparin are associated with increased risk for clots, as well as AK200 dialysis machine. VKA and high volume of blood treated during one session are protective. Antiplatelet drugs, venous iron, ultrafiltration rate, hemoglobin concentration, and CRP do not have significant impact on the risk of clots.